The Extracellular Matrix (ECM) is a major component of all the organs. This dynamic structure is involved not only in cell adhesion, but also in physiological processes, including cell differentiation, migration, and maturation, tissue homeostasis, biochemical signal retention and mediation, and growth factors’ retention. Moreover, the ECM can be abnormally Read more…
The extracellular matrix (ECM) is the non-cellular component of tissue. Its is mainly composed of structural and adhesion molecules, such as hyaluronic acid, collagene, proteoglycans, fibronectin, elastin, although its specific composition and structure vary between different tissues. It is a dynamic structure, which is involved not only in the cell Read more…
In 2020, Nia et al. published in the journal Science a review entitled ‘Physical traits of cancer‘. In this article, the authors proposed 4 distinct physical traits of cancer linked to the biomechanical abnormalities observed in tumoral tissues : an enhanced solid stress (compression and tension), i.e. the mechanical forces Read more…
We are very please to welcome Dr Isabelle Van Seuningen (Director of CANTHER laboratories & Director of ONCOLille Cancer Institute) and Dr Vincent Senez (Research Director CNRS/CANTHER Laboratory/ONCOLille Institute) in our serie of talk about the uses of BIOMIMESYS®. They explain why they use this technology on cancer research with Read more…
When Tuesday, February 23, 2021 – 1PM (CET) / 8PM (CST) / 9PM (JST) / 7AM (EST) Thursday, February 25, 2021 – 9AM (CET) / 4PM (CST) / 5PM (JST) / 3AM (EST) Where Online, using zoom.us and live on Youtube What 3D cell culture systems have recently as promising Read more…
We are developing a new BIOMIMESYS® hydroscaffold for neuronal cells. First results are very promising because neurons grow and form neurites. Moreover cells lived longer than in monolayer culture. We are currently finalizing this new hydroscaffold to find the best conditions of 3D neuron culture, but BIOMIMESYS® Brain will be soon Read more…
Abstract Bevacizumab is a humanized monoclonal antibody directed against the pro-angiogenic factor vascular and endothelial growth factor-A (VEGF-A) used in the treatment of glioblastomas. Although most patients respond initially to this treatment, studies have shown that glioblastomas eventually recur. Several non-mutually exclusive theories based on the anti-angiogenic effect of bevacizumab Read more…
Cells have diverse circuitry to sense and respond to extrinsic metabolic signals. Extracellular matrix (ECM) reorganization which is central to both tissue expansion and regeneration. ECM remodeling is also a signature of pathological processes, such as tumorigenesis. In this study from Sullivan et al., they show that increased migration in Read more…
Biosynthetic skeleton for ECM development.